Do you know your cholesterol levels and cardiovascular risk? Although treatment has been available for decades, meeting goals for cholesterol management is still not easy on patients – even when they do everything right, sometimes it’s still not enough. At Esperion, we work to discover, develop and commercialize medicines that help patients to reduce their cardiovascular risk.
We are growing our pipeline with an ongoing cardiovascular outcomes trial (CVOT) and an investigational early-stage oral PCSK9 inhibitor program.
Our Mission: Lowering Cholesterol with Novel and Combination Medicines
Esperion is passionately committed to developing and commercializing oral, LDL-C lowering therapies for patients with hypercholesterolemia.
Our Core Values
We promote an inclusive and supportive environment that, regardless of title or rank, fosters open discussion and debate.
We challenge the status quo with entrepreneurial spirit as we remain steadfastly committed to problem-solving with agility, resilience, and creativity.
We value each other, and we invest in building strong relationships and creating opportunities for personal and professional growth.
We are committed to making a difference for patients living with hypercholesterolemia and will confront every challenge with optimism and resourcefulness.
We hold ourselves and each other to the highest level of personal and professional integrity, by owning what we say and delivering on our commitments.